Emeline Tabouret
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emeline Tabouret has a total of 519 co-authors. Here are the top co-authors by number of shared publications:
- Olivier Chinot
Hôpital La Timone, Marseille, France
18 shared publications Romain Appay
Inst Neurophysiopathol, Aix-Marseille Univ, CNRS, INP, GlioME Team, Marseille, France
14 shared publications- Dominique Figarella-Branger
Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, GlioME Team, CHU Timone, Service d‘Anatomie Pathologique et de Neuropathologie , Marseille
10 shared publications - Nicolas André
AP-HM
10 shared publications Olivier Chinot
Aix‐Marseille Univ, CNRS, INP, Inst Neurophysiopathol, GlioME Team Marseille France
10 shared publications- Abhishek Chatterjee
Department of Neurosurgery Tata Memorial Centre Homi Bhabha National Institute Dr. E. Borges Marg Mumbai India
9 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Map demonstrating the countries represented by contributing institutions.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Map demonstrating the countries represented by contributing institutions.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Long-term survivors ≥ 5 years (n = 12)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Long-term survivors ≥ 5 years (n = 12)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Patients with G34V mutation subtype (n = 9)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Patients with G34V mutation subtype (n = 9)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Initial chemotherapy combinations
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Initial chemotherapy combinations
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Kaplan-Meier survival plots demonstrating overall survival. (A). Initial chemotherapy (all ages): TMZ-based vs TMZ/CCNU. (B). Initial chemotherapy (under 18 years old): TMZ-based vs TMZ/CCNU. (C). Re-irradiation: yes vs no. (D). ATRX mutation: yes vs no. (E). PDGFRA amplification: yes vs no. (F) TP53 mutation: yes vs no. (G). PDGFRA mutation: yes vs no.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Kaplan-Meier survival plots demonstrating overall survival. (A). Initial chemotherapy (all ages): TMZ-based vs TMZ/CCNU. (B). Initial chemotherapy (under 18 years old): TMZ-based vs TMZ/CCNU. (C). Re-irradiation: yes vs no. (D). ATRX mutation: yes vs no. (E). PDGFRA amplification: yes vs no. (F) TP53 mutation: yes vs no. (G). PDGFRA mutation: yes vs no.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Purpose: Knowledge of prognostic factors and long-term survival in patients with diffuse hemispheric glioma, H3 G34–mutant (DHG, H3 G34), remains limited in this tumor with a poor prognosis.Experimental Design:This retrospective, multi-institutional study investigated prognostic variables for patients with DHG, H3 G34, and their association with progression-free survival (PFS) and overall survival (OS). Uni- and multivariable Cox proportional hazard models were applied with multiple imputed datasets.Results:A total of 153 patients (142 G34R, 9 G34V, 2 via DNA methylation) were included. The median age at diagnosis was 17 years (range, 2–45). Initial gross/near total resection (GTR/NTR) was achieved in 43% of patients. Radiation was given in 91% (85% focal irradiation), and initial chemotherapy was given in 87% [70% temozolomide-based (TMZ), 25% TMZ/lomustine, 5% non-TMZ]. Median OS was 24 months [interquartile range (IQR), 22–28] with a median PFS of 14 months (IQR, 12–19). Twelve patients (8%) were found to be long-term survivors (≥5 years). Exploratory multivariable analysis showed that adjuvant radiotherapy [HR, 0.076; 95% confidence interval (CI), 0.033–0.17] and achieving GTR/NTR compared with < NTR (HR, 0.51; 95% CI, 0.33–0.78) were associated with improved PFS. Multivariable analysis showed improved OS with increasing age at diagnosis (HR, 0.70; 95% CI, 0.57–0.87), initial radiotherapy (HR, 0.38; 95% CI, 0.15–0.96), and initial GTR/NTR compared with < NTR (HR, 0.60; 95% CI, 0.37–0.97).Conclusions:This cohort highlights prognostic factors for patients with DHG, H3 G34, and describes relapse patterns and therapy approaches. Clinical trials and prospective registries are needed to improve outcomes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Purpose: Knowledge of prognostic factors and long-term survival in patients with diffuse hemispheric glioma, H3 G34–mutant (DHG, H3 G34), remains limited in this tumor with a poor prognosis.Experimental Design:This retrospective, multi-institutional study investigated prognostic variables for patients with DHG, H3 G34, and their association with progression-free survival (PFS) and overall survival (OS). Uni- and multivariable Cox proportional hazard models were applied with multiple imputed datasets.Results:A total of 153 patients (142 G34R, 9 G34V, 2 via DNA methylation) were included. The median age at diagnosis was 17 years (range, 2–45). Initial gross/near total resection (GTR/NTR) was achieved in 43% of patients. Radiation was given in 91% (85% focal irradiation), and initial chemotherapy was given in 87% [70% temozolomide-based (TMZ), 25% TMZ/lomustine, 5% non-TMZ]. Median OS was 24 months [interquartile range (IQR), 22–28] with a median PFS of 14 months (IQR, 12–19). Twelve patients (8%) were found to be long-term survivors (≥5 years). Exploratory multivariable analysis showed that adjuvant radiotherapy [HR, 0.076; 95% confidence interval (CI), 0.033–0.17] and achieving GTR/NTR compared with < NTR (HR, 0.51; 95% CI, 0.33–0.78) were associated with improved PFS. Multivariable analysis showed improved OS with increasing age at diagnosis (HR, 0.70; 95% CI, 0.57–0.87), initial radiotherapy (HR, 0.38; 95% CI, 0.15–0.96), and initial GTR/NTR compared with < NTR (HR, 0.60; 95% CI, 0.37–0.97).Conclusions:This cohort highlights prognostic factors for patients with DHG, H3 G34, and describes relapse patterns and therapy approaches. Clinical trials and prospective registries are needed to improve outcomes.
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Glioblastome et angiogenèse : profils évolutifs, interaction avec l'invasivité et implications thérapeutiques
Les glioblastomes sont les tumeurs primitives cérébrales les plus agressives de l’adulte. Elles sont caractérisées par une importante néo-angiogenèse, conduisant au développement des anti-VEGF chez ces patients. L’objectif de cette thèse était d’identifier de potentiels marqueurs prédictifs de l’activité du bevacizumab et d’analyser le profil évolutif des facteurs de l’angiogenèse. En situation de récidive d’un gliome de haut grade, si aucun facteur clinique ne semble permettre d’identifier un sous-groupe de patients bénéficiant particulièrement du bevacizumab, les taux plasmatiques avant traitement de MMP2 et MMP9, inversement corrélés entre eux suggérant un rôle biologique distinct mais relié, semblent associés à la réponse, la survie sans progression et la survie globale de patients porteurs de gliome de haut grade traités à la récidive par bevacizumab. Le rôle potentiel de ces marqueurs est renforcé par la cinétique de leurs taux plasmatiques observé sous traitement, Nous avons mis en évidence des résultats superposables chez des patientes porteuses de cancers du sein inflammatoires traités par bevacizumab en situation néo-adjuvante, renforçant l’intérêt de ces marqueurs. Par ailleurs, l’analyse de la signature angiogénique tissulaire des glioblastomes nouvellement diagnostiqués et récidivants nous a permis d’observer une modification de l’expression des facteurs de l’angiogenèse avec un possible switch de la voie VEGFR2-HIF1α en faveur de la voie CXCL12-CXCR4 à la récidive. Ces différents résultats permettent d’ouvrir de nouvelles perspectives dans le ciblage de l’angiogenèse et dans l’approche thérapeutique de patients porteurs de gliome de haut grade.
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Glioblastome et angiogenèse : profils évolutifs, interaction avec l'invasivité et implications thérapeutiques
Les glioblastomes sont les tumeurs primitives cérébrales les plus agressives de l’adulte. Elles sont caractérisées par une importante néo-angiogenèse, conduisant au développement des anti-VEGF chez ces patients. L’objectif de cette thèse était d’identifier de potentiels marqueurs prédictifs de l’activité du bevacizumab et d’analyser le profil évolutif des facteurs de l’angiogenèse. En situation de récidive d’un gliome de haut grade, si aucun facteur clinique ne semble permettre d’identifier un sous-groupe de patients bénéficiant particulièrement du bevacizumab, les taux plasmatiques avant traitement de MMP2 et MMP9, inversement corrélés entre eux suggérant un rôle biologique distinct mais relié, semblent associés à la réponse, la survie sans progression et la survie globale de patients porteurs de gliome de haut grade traités à la récidive par bevacizumab. Le rôle potentiel de ces marqueurs est renforcé par la cinétique de leurs taux plasmatiques observé sous traitement, Nous avons mis en évidence des résultats superposables chez des patientes porteuses de cancers du sein inflammatoires traités par bevacizumab en situation néo-adjuvante, renforçant l’intérêt de ces marqueurs. Par ailleurs, l’analyse de la signature angiogénique tissulaire des glioblastomes nouvellement diagnostiqués et récidivants nous a permis d’observer une modification de l’expression des facteurs de l’angiogenèse avec un possible switch de la voie VEGFR2-HIF1α en faveur de la voie CXCL12-CXCR4 à la récidive. Ces différents résultats permettent d’ouvrir de nouvelles perspectives dans le ciblage de l’angiogenèse et dans l’approche thérapeutique de patients porteurs de gliome de haut grade.
- Open Access
- 9 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (11) , 2243-2254
Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Purpose: Knowledge of prognostic factors and long-term survival in patients with diffuse hemispheric glioma, H3 G34–mutant (DHG, H3 G34), remains limited in this tumor with a poor prognosis. Experimental Design: This retrospective, multi-institutional study investigated prognostic variables for patients with DHG, H3 G34, and their association with progression-free survival (PFS) and overall survival (OS). Uni- and multivariable Cox proportional hazard models were applied with multiple imputed datasets. Results: A total of 153 patients (142 G34R, 9 G34V, 2 via DNA methylation) were included. The median age at diagnosis was 17 years (range, 2–45). Initial gross/near total resection (GTR/NTR) was achieved in 43% of patients. Radiation was given in 91% (85% focal irradiation), and initial chemotherapy was given in 87% [70% temozolomide-based (TMZ), 25% TMZ/lomustine, 5% non-TMZ]. Median OS was 24 months [interquartile range (IQR), 22–28] with a median PFS of 14 months (IQR, 12–19). Twelve patients (8%) were found to be long-term survivors (≥5 years). Exploratory multivariable analysis showed that adjuvant radiotherapy [HR, 0.076; 95% confidence interval (CI), 0.033–0.17] and achieving GTR/NTR compared with < NTR (HR, 0.51; 95% CI, 0.33–0.78) were associated with improved PFS. Multivariable analysis showed improved OS with increasing age at diagnosis (HR, 0.70; 95% CI, 0.57–0.87), initial radiotherapy (HR, 0.38; 95% CI, 0.15–0.96), and initial GTR/NTR compared with < NTR (HR, 0.60; 95% CI, 0.37–0.97). Conclusions: This cohort highlights prognostic factors for patients with DHG, H3 G34, and describes relapse patterns and therapy approaches. Clinical trials and prospective registries are needed to improve outcomes.
- 9 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (11) , 2243-2254
Open AccessClinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Purpose: Knowledge of prognostic factors and long-term survival in patients with diffuse hemispheric glioma, H3 G34–mutant (DHG, H3 G34), remains limited in this tumor with a poor prognosis. Experimental Design: This retrospective, multi-institutional study investigated prognostic variables for patients with DHG, H3 G34, and their association with progression-free survival (PFS) and overall survival (OS). Uni- and multivariable Cox proportional hazard models were applied with multiple imputed datasets. Results: A total of 153 patients (142 G34R, 9 G34V, 2 via DNA methylation) were included. The median age at diagnosis was 17 years (range, 2–45). Initial gross/near total resection (GTR/NTR) was achieved in 43% of patients. Radiation was given in 91% (85% focal irradiation), and initial chemotherapy was given in 87% [70% temozolomide-based (TMZ), 25% TMZ/lomustine, 5% non-TMZ]. Median OS was 24 months [interquartile range (IQR), 22–28] with a median PFS of 14 months (IQR, 12–19). Twelve patients (8%) were found to be long-term survivors (≥5 years). Exploratory multivariable analysis showed that adjuvant radiotherapy [HR, 0.076; 95% confidence interval (CI), 0.033–0.17] and achieving GTR/NTR compared with < NTR (HR, 0.51; 95% CI, 0.33–0.78) were associated with improved PFS. Multivariable analysis showed improved OS with increasing age at diagnosis (HR, 0.70; 95% CI, 0.57–0.87), initial radiotherapy (HR, 0.38; 95% CI, 0.15–0.96), and initial GTR/NTR compared with < NTR (HR, 0.60; 95% CI, 0.37–0.97). Conclusions: This cohort highlights prognostic factors for patients with DHG, H3 G34, and describes relapse patterns and therapy approaches. Clinical trials and prospective registries are needed to improve outcomes.